Atopic Dermatitis Market

Market Overview:

The 7 major atopic dermatitis markets reached a value of US$ 16,816.8 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 37,213.7 Million by 2034, exhibiting a growth rate (CAGR) of 7.49% during 2024-2034.

The atopic dermatitis market has been comprehensively analyzed in IMARC's new report titled "Atopic Dermatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Atopic dermatitis refers to a type of non-communicable eczema in which the skin barrier becomes dry and irritated. Though this ailment is more frequent among children, it can affect people of any age. Many patients with atopic dermatitis have coexisting symptoms such as hay fever, asthma, and food allergies. Eczema can manifest itself in many ways and in various parts of the body at different times, but it nearly always includes itchy skin. Some of the common symptoms also include dry or hypersensitive skin, inflamed or discolored skin, rough, leathery, or scaly skin, swelling in the afflicted area, and oozing or blistering of the skin. There are several conditions that might result in a skin rash that resembles atopic dermatitis. Nonetheless, a closer study of the appearance and location of the inflammation, accompanied by reviewing their health history and allergy testing, is typically enough to provide a diagnosis, but a doctor may additionally request a further patch test.

The increasing prevalence of dermatological disorders caused by epidermal gene mutations, complex interactions of immune dysregulation, and environmental factors that disrupt the epidermis resulting in intensely pruritic skin lesions is primarily driving the global atopic dermatitis market. In addition to this, the growing food and skin allergies among infants are further bolstering the market growth. Moreover, the rising incidences of eczema among the geriatric population as they are more susceptible to having a history of flexion dermatitis is also acting as a significant growth-inducing factor. Besides this, the escalating utilization of oral corticosteroids for severe cases when the disease has covered large areas of the body or in case of any complication with other therapies is further creating a positive outlook for the market. Additionally, the emerging popularity of ultraviolet phototherapy as a second-line intervention for both chronic and acute atopic dermatitis is also propelling the global market. UV radiation targets inflammatory cells on the skin, thereby inducing positive immunosuppressive effects by altering cytokine production. Furthermore, the widespread adoption of novel biologics owing to their high efficacy, safety, and targeted approach to treating the disease is expected to drive the atopic dermatitis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the atopic dermatitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for atopic dermatitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the atopic dermatitis market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the atopic dermatitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the atopic dermatitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current atopic dermatitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the atopic dermatitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the atopic dermatitis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the atopic dermatitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the size of the atopic dermatitis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of atopic dermatitis ?
• What will be the growth rate of patients across the seven major markets?
   

Atopic Dermatitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for atopic dermatitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the atopic dermatitis market?